Clinical Considerations in Renal Cell Carcinoma: Current Evidence, Guideline Recommendations, and a View to the Future

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with RCC.

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This educational program is intended for oncologists, physician assistants/physician associates, nurses, pharmacists, and other healthcare professionals involved in the care of patients with RCC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with RCC most likely to benefit from targeted and/or immune checkpoint inhibitor–based combination therapies based on risk and biomarker assessment, along with patient medical and treatment history
  • Select optimal first-line treatment for individual patients with advanced or metastatic RCC, considering current and emerging options, available clinical evidence, expert recommendations, and patient preferences
  • Plan evidence-based and expert recommended therapeutic sequencing strategies for patients with RCC
  • Manage specific disease-related complications or adverse events associated with currently approved treatments for advanced RCC
  • Select patients with RCC who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences
Additional information

Supported by educational grants from AVEO Pharmaceuticals, Inc. (“AVEO Oncology”) and Eisai. 

Supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 1.75 AAPA Category 1 CME credit
  • 1.75 ACPE contact hours
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation
Course opens: 
Course expires: 

Katy E. Beckermann, MD, PhD
Assistant Professor
Department of Internal Medicine
Division of Hematology/Oncology
Vanderbilt University 
Nashville, Tennessee

Stephanie A. Berg, DO
Instructor of Medicine
Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Medical Director, International Strategic Initiatives
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts 


NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Katy E. Beckermann, MD, PhD
Alpine Bioscience LLC: Consultant/Advisor/Speaker
Aravive: Consultant/Advisor/Speaker; Grant/Research Support
Arsenal Bio: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
AVEO Pharmaceuticals, Inc.: Consultant/Advisor/Speaker
Bristol-Myers Squibb Company: Consultant/Advisor/Speaker
Bristol Myers Squibb/LCFA/IASLC: Grant/Research Support
Exelixis Inc.: Consultant/Advisor/Speaker
Merck & Co., Inc.: Consultant/Advisor/Speaker
SeaGen: Consultant/Advisor/Speaker
sanofi-aventis U.S.: Consultant/Advisor/Speaker

Stephanie A. Berg, DO
Bristol-Myers Squibb Company: Consultant/Advisor/Speaker
Eisai Inc.: Consultant/Advisor/Speaker
Exelixis Inc.: Consultant/Advisor/Speaker

Toni K. Choueiri, MD
Bristol-Myers Squibb Company: Consultant/Advisor/Speaker
EMD Serono: Consultant/Advisor/Speaker
Exelixis/Ipsen: Consultant/Advisor/Speaker
Merck & Co., Inc.: Consultant/Advisor/Speaker
MJH Life Sciences: Consultant/Advisor/Speaker
Pfizer Inc.: Consultant/Advisor/Speaker
Roche Laboratories, Inc.: Consultant/Advisor/Speaker

NCCN and CCO Staff Disclosures

The CCO planner/content peer reviewer listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated.  

Taryn O’Loughlin Gross, PhD
BTG Pharmaceuticals: Independent Contractor
Endo Pharmaceuticals: Independent Contractor
Harmony Biosciences: Independent Contractor
Instalab: Independent Contractor
Paratek Pharmaceuticals: Independent Contractor

None of the other planners/managers/reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.75 contact hours.

NCCN designates this application-based continuing education activity for 1.75 contact hours (0.175 CEUs) of continuing education credit. UAN: JA4008196-0000-23-094-H01-P

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credits. Approval is valid until July 21, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.75 AAPA Category 1 CME credit
  • 1.75 ACPE contact hours
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing